The WEE1 inhibitor ZN-c3 has been granted fast track designation by the FDA for treatment of patients with uterine serous carcinoma (27, 28) and is included in nine other clinical trials testing its efficacy in various other types of cancer. Here, WEE1 is linked to cancer.